Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
Titel:
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
Auteur:
Bansilal, Sameer Bloomgarden, Zachary Halperin, Jonathan L. Hellkamp, Anne S. Lokhnygina, Yuliya Patel, Manesh R. Becker, Richard C. Breithardt, Günter Hacke, Werner Hankey, Graeme J. Nessel, Christopher C. Singer, Daniel E. Berkowitz, Scott D. Piccini, Jonathan P. Mahaffey, Kenneth W. Fox, Keith A.A.
Verschenen in:
American heart journal
Paginering:
Jaargang 170 (2015) nr. 4 pagina's 6.8199999326E10 p.